Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€160.82

€160.82

1.270%
2.02
1.270%
€175.79
 
20.06.24 / Tradegate WKN: A1J84E / Symbol: ABBV / Name: AbbVie / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

AbbVie Inc. Stock

There is an upward development for AbbVie Inc. compared to yesterday, with an increase of €2.02 (1.270%).
With 26 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 175 € there is a slightly positive potential of 8.82% for AbbVie Inc. compared to the current price of 160.82 €.
Our community identified positive and negative aspects for AbbVie Inc. stock for the coming years. 1 users see the criterium "Expected dividend yield" as a plus for the AbbVie Inc. stock. On the other hand our users think that "Debt" could be a problem in the future.

AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.

Pros and Cons of AbbVie Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of AbbVie Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
AbbVie Inc. 1.270% 3.715% 5.733% 27.231% 14.789% 68.698% 131.396%
Pfizer Inc. 1.980% 0.660% -1.744% -28.199% -0.690% -20.746% -29.306%
Elanco Animal Health Inc. 0.780% 0.819% 7.461% 81.387% 25.710% -41.874% -
Biogen Inc. 1.640% -3.169% -1.126% -21.752% -10.602% -35.555% 1.103%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17

Based on the provided financial statements, AbbVie Inc., a prominent company in the pharmaceutical industry, appears to be maintaining a strong financial position. The company has demonstrated consistent growth in revenues and net income over the years. However, there are also challenges in certain aspects that could impact the company's financial health.

Revenue growth: From 2020 to 2022, AbbVie's total revenues increased from €45.8 billion to $58.0 billion, signifying a healthy growth rate. This suggests a strong demand for their products and services in the pharmaceuticals industry.

Net income growth: Net income has shown a steady increase. In 2020, the net income stood at €4.6 billion, which rose to €11.5 billion in 2021 and further increased to $11.8 billion in 2022.

Comments

Prediction Buy
Perf. (%) -0.07%
Target price 186.720
Change
Ends at 20.06.25

AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $200.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 2.12%
Target price 176.966
Change
Ends at 18.06.25

AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Piper Sandler from $185.00 to $190.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 6.86%
Target price 169.923
Change
Ends at 05.06.25

AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $185.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
Show more

News

10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year: https://g.foolcdn.com/editorial/images/781113/gettyimages-1720247749.jpg
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year

The power of compounding is very real. It is a process that takes time, as dividend investing is not about year 1 dividend income, but rather about year 10+. In today's video, we will look at the

2 Dividend Stocks That Could Pay You for Life: https://g.foolcdn.com/editorial/images/780433/person-sitting-and-working-at-a-desk.jpg
2 Dividend Stocks That Could Pay You for Life

People invest in dividend stocks for various reasons. Some want the passive income; others reinvest the cash to boost long-term returns; still others find that corporations that can dish out regular

Top Stocks to Buy in June: https://g.foolcdn.com/editorial/images/779492/gettyimages-1720247749.jpg
Top Stocks to Buy in June

When you look at the stock market, valuations can seem stretched for a lot of the megacap names -- not all -- but there are still plenty of deals to be had. In today's video, I will look into a few